AB013. S3A-2. The future potential of immunotherapy in biliary tract cancer

Nilofer S. Azad

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University, Baltimore, Maryland, USA

Correspondence to: Nilofer S. Azad. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University, Baltimore, Maryland, USA. Email: nazad2@jhmi.edu.

Abstract: Immunotherapy has revolutionized the treatment of cancer. For a minority of patients with solid tumors, it has resulted in durable responses, sometimes even cure. Immunotherapy modalities have focused heavily on immune checkpoint inhibitor therapy, but also include adoptive immunotherapy, vaccine based approaches, and the use of other classes of agents to modulate the immune system including epigenetic and molecularly targeted agents. Initial reports of the efficacy of immune approaches in biliary tract cancers have been mixed, with some scattered but meaningful responses. Novel agents and combinations are an important area of translational and clinical research. This presentation will focus on recent data showing the present knowledge of immunotherapy outcomes in biliary tract cancers as well as emerging areas.

Keywords: Immunotherapy; biliary tract cancer; cholangiocarcinoma